nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—ADORA2A—Pentoxifylline—systemic scleroderma	0.832	1	CbGbCtD
Regadenoson—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000298	0.00177	CcSEcCtD
Regadenoson—Abdominal pain—Captopril—systemic scleroderma	0.000297	0.00177	CcSEcCtD
Regadenoson—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000296	0.00176	CcSEcCtD
Regadenoson—Nausea—Pentoxifylline—systemic scleroderma	0.000295	0.00175	CcSEcCtD
Regadenoson—Malaise—Lisinopril—systemic scleroderma	0.000294	0.00175	CcSEcCtD
Regadenoson—Diarrhoea—Mometasone—systemic scleroderma	0.000293	0.00174	CcSEcCtD
Regadenoson—Syncope—Lisinopril—systemic scleroderma	0.000292	0.00174	CcSEcCtD
Regadenoson—Shock—Mycophenolic acid—systemic scleroderma	0.000291	0.00173	CcSEcCtD
Regadenoson—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00029	0.00172	CcSEcCtD
Regadenoson—Hypotension—Leflunomide—systemic scleroderma	0.000289	0.00172	CcSEcCtD
Regadenoson—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000288	0.00171	CcSEcCtD
Regadenoson—Palpitations—Lisinopril—systemic scleroderma	0.000288	0.00171	CcSEcCtD
Regadenoson—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000288	0.00171	CcSEcCtD
Regadenoson—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000287	0.00171	CcSEcCtD
Regadenoson—Loss of consciousness—Lisinopril—systemic scleroderma	0.000287	0.0017	CcSEcCtD
Regadenoson—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000286	0.0017	CcSEcCtD
Regadenoson—Cough—Lisinopril—systemic scleroderma	0.000285	0.00169	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000283	0.00168	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000282	0.00168	CcSEcCtD
Regadenoson—Insomnia—Leflunomide—systemic scleroderma	0.00028	0.00167	CcSEcCtD
Regadenoson—Abdominal distension—Prednisone—systemic scleroderma	0.00028	0.00166	CcSEcCtD
Regadenoson—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00028	0.00166	CcSEcCtD
Regadenoson—Paraesthesia—Leflunomide—systemic scleroderma	0.000278	0.00165	CcSEcCtD
Regadenoson—Chest pain—Lisinopril—systemic scleroderma	0.000278	0.00165	CcSEcCtD
Regadenoson—Arthralgia—Lisinopril—systemic scleroderma	0.000278	0.00165	CcSEcCtD
Regadenoson—Myalgia—Lisinopril—systemic scleroderma	0.000278	0.00165	CcSEcCtD
Regadenoson—Anxiety—Lisinopril—systemic scleroderma	0.000277	0.00164	CcSEcCtD
Regadenoson—Dyspnoea—Leflunomide—systemic scleroderma	0.000276	0.00164	CcSEcCtD
Regadenoson—Hypotension—Mycophenolic acid—systemic scleroderma	0.000276	0.00164	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000276	0.00164	CcSEcCtD
Regadenoson—Discomfort—Lisinopril—systemic scleroderma	0.000274	0.00163	CcSEcCtD
Regadenoson—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.000274	0.00163	CcSEcCtD
Regadenoson—Vomiting—Mometasone—systemic scleroderma	0.000272	0.00162	CcSEcCtD
Regadenoson—Feeling abnormal—Azathioprine—systemic scleroderma	0.00027	0.00161	CcSEcCtD
Regadenoson—Rash—Mometasone—systemic scleroderma	0.00027	0.0016	CcSEcCtD
Regadenoson—Asthenia—Captopril—systemic scleroderma	0.00027	0.0016	CcSEcCtD
Regadenoson—Dermatitis—Mometasone—systemic scleroderma	0.00027	0.0016	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000269	0.0016	CcSEcCtD
Regadenoson—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000268	0.00159	CcSEcCtD
Regadenoson—Headache—Mometasone—systemic scleroderma	0.000268	0.00159	CcSEcCtD
Regadenoson—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000268	0.00159	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000267	0.00159	CcSEcCtD
Regadenoson—Insomnia—Mycophenolic acid—systemic scleroderma	0.000267	0.00159	CcSEcCtD
Regadenoson—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000266	0.00158	CcSEcCtD
Regadenoson—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000265	0.00158	CcSEcCtD
Regadenoson—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000265	0.00158	CcSEcCtD
Regadenoson—Pain—Leflunomide—systemic scleroderma	0.000265	0.00157	CcSEcCtD
Regadenoson—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000263	0.00157	CcSEcCtD
Regadenoson—Somnolence—Mycophenolic acid—systemic scleroderma	0.000263	0.00156	CcSEcCtD
Regadenoson—Shock—Lisinopril—systemic scleroderma	0.000262	0.00156	CcSEcCtD
Regadenoson—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000261	0.00155	CcSEcCtD
Regadenoson—Tachycardia—Lisinopril—systemic scleroderma	0.00026	0.00154	CcSEcCtD
Regadenoson—Abdominal pain—Azathioprine—systemic scleroderma	0.000259	0.00154	CcSEcCtD
Regadenoson—Skin disorder—Lisinopril—systemic scleroderma	0.000259	0.00154	CcSEcCtD
Regadenoson—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000258	0.00153	CcSEcCtD
Regadenoson—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000257	0.00153	CcSEcCtD
Regadenoson—Diarrhoea—Captopril—systemic scleroderma	0.000257	0.00153	CcSEcCtD
Regadenoson—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000256	0.00152	CcSEcCtD
Regadenoson—Feeling abnormal—Leflunomide—systemic scleroderma	0.000255	0.00152	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000255	0.00152	CcSEcCtD
Regadenoson—Nausea—Mometasone—systemic scleroderma	0.000254	0.00151	CcSEcCtD
Regadenoson—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000253	0.00151	CcSEcCtD
Regadenoson—Pain—Mycophenolic acid—systemic scleroderma	0.000253	0.0015	CcSEcCtD
Regadenoson—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000252	0.0015	CcSEcCtD
Regadenoson—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000251	0.00149	CcSEcCtD
Regadenoson—Cough—Mycophenolate mofetil—systemic scleroderma	0.000249	0.00148	CcSEcCtD
Regadenoson—Hypotension—Lisinopril—systemic scleroderma	0.000249	0.00148	CcSEcCtD
Regadenoson—Dizziness—Captopril—systemic scleroderma	0.000249	0.00148	CcSEcCtD
Regadenoson—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000248	0.00147	CcSEcCtD
Regadenoson—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000247	0.00147	CcSEcCtD
Regadenoson—Urticaria—Leflunomide—systemic scleroderma	0.000246	0.00146	CcSEcCtD
Regadenoson—Abdominal pain—Leflunomide—systemic scleroderma	0.000245	0.00146	CcSEcCtD
Regadenoson—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000244	0.00145	CcSEcCtD
Regadenoson—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000243	0.00145	CcSEcCtD
Regadenoson—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000243	0.00145	CcSEcCtD
Regadenoson—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000243	0.00145	CcSEcCtD
Regadenoson—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000243	0.00145	CcSEcCtD
Regadenoson—Myocardial infarction—Prednisone—systemic scleroderma	0.000243	0.00144	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000242	0.00144	CcSEcCtD
Regadenoson—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000242	0.00144	CcSEcCtD
Regadenoson—Hypersensitivity—Azathioprine—systemic scleroderma	0.000242	0.00144	CcSEcCtD
Regadenoson—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000242	0.00144	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000242	0.00144	CcSEcCtD
Regadenoson—Insomnia—Lisinopril—systemic scleroderma	0.000241	0.00143	CcSEcCtD
Regadenoson—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00024	0.00143	CcSEcCtD
Regadenoson—Paraesthesia—Lisinopril—systemic scleroderma	0.000239	0.00142	CcSEcCtD
Regadenoson—Vomiting—Captopril—systemic scleroderma	0.000239	0.00142	CcSEcCtD
Regadenoson—Dyspnoea—Lisinopril—systemic scleroderma	0.000237	0.00141	CcSEcCtD
Regadenoson—Rash—Captopril—systemic scleroderma	0.000237	0.00141	CcSEcCtD
Regadenoson—Dermatitis—Captopril—systemic scleroderma	0.000237	0.00141	CcSEcCtD
Regadenoson—Somnolence—Lisinopril—systemic scleroderma	0.000237	0.00141	CcSEcCtD
Regadenoson—Headache—Captopril—systemic scleroderma	0.000235	0.0014	CcSEcCtD
Regadenoson—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000234	0.00139	CcSEcCtD
Regadenoson—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000233	0.00139	CcSEcCtD
Regadenoson—Asthma—Methotrexate—systemic scleroderma	0.000232	0.00138	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00023	0.00137	CcSEcCtD
Regadenoson—Shock—Mycophenolate mofetil—systemic scleroderma	0.000229	0.00136	CcSEcCtD
Regadenoson—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000229	0.00136	CcSEcCtD
Regadenoson—Hypersensitivity—Leflunomide—systemic scleroderma	0.000228	0.00136	CcSEcCtD
Regadenoson—Pain—Lisinopril—systemic scleroderma	0.000228	0.00135	CcSEcCtD
Regadenoson—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000228	0.00135	CcSEcCtD
Regadenoson—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000226	0.00135	CcSEcCtD
Regadenoson—Bradycardia—Prednisone—systemic scleroderma	0.000226	0.00135	CcSEcCtD
Regadenoson—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000225	0.00134	CcSEcCtD
Regadenoson—Diarrhoea—Azathioprine—systemic scleroderma	0.000224	0.00133	CcSEcCtD
Regadenoson—Nausea—Captopril—systemic scleroderma	0.000223	0.00133	CcSEcCtD
Regadenoson—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000223	0.00132	CcSEcCtD
Regadenoson—Asthenia—Leflunomide—systemic scleroderma	0.000222	0.00132	CcSEcCtD
Regadenoson—Feeling abnormal—Lisinopril—systemic scleroderma	0.000219	0.0013	CcSEcCtD
Regadenoson—Connective tissue disorder—Prednisone—systemic scleroderma	0.000219	0.0013	CcSEcCtD
Regadenoson—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000218	0.0013	CcSEcCtD
Regadenoson—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000218	0.00129	CcSEcCtD
Regadenoson—Dizziness—Azathioprine—systemic scleroderma	0.000217	0.00129	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000212	0.00126	CcSEcCtD
Regadenoson—Asthenia—Mycophenolic acid—systemic scleroderma	0.000212	0.00126	CcSEcCtD
Regadenoson—Diarrhoea—Leflunomide—systemic scleroderma	0.000212	0.00126	CcSEcCtD
Regadenoson—Urticaria—Lisinopril—systemic scleroderma	0.000211	0.00126	CcSEcCtD
Regadenoson—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000211	0.00125	CcSEcCtD
Regadenoson—Abdominal pain—Lisinopril—systemic scleroderma	0.00021	0.00125	CcSEcCtD
Regadenoson—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000209	0.00124	CcSEcCtD
Regadenoson—Vomiting—Azathioprine—systemic scleroderma	0.000209	0.00124	CcSEcCtD
Regadenoson—Eye disorder—Prednisone—systemic scleroderma	0.000208	0.00124	CcSEcCtD
Regadenoson—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000208	0.00124	CcSEcCtD
Regadenoson—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000207	0.00123	CcSEcCtD
Regadenoson—Rash—Azathioprine—systemic scleroderma	0.000207	0.00123	CcSEcCtD
Regadenoson—Dermatitis—Azathioprine—systemic scleroderma	0.000207	0.00123	CcSEcCtD
Regadenoson—Flushing—Prednisone—systemic scleroderma	0.000206	0.00123	CcSEcCtD
Regadenoson—Headache—Azathioprine—systemic scleroderma	0.000205	0.00122	CcSEcCtD
Regadenoson—Dizziness—Leflunomide—systemic scleroderma	0.000205	0.00122	CcSEcCtD
Regadenoson—Renal failure—Methotrexate—systemic scleroderma	0.000204	0.00121	CcSEcCtD
Regadenoson—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000202	0.0012	CcSEcCtD
Regadenoson—Angiopathy—Prednisone—systemic scleroderma	0.000202	0.0012	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000201	0.0012	CcSEcCtD
Regadenoson—Immune system disorder—Prednisone—systemic scleroderma	0.000201	0.00119	CcSEcCtD
Regadenoson—Pain—Mycophenolate mofetil—systemic scleroderma	0.000199	0.00119	CcSEcCtD
Regadenoson—Vomiting—Leflunomide—systemic scleroderma	0.000197	0.00117	CcSEcCtD
Regadenoson—Hypersensitivity—Lisinopril—systemic scleroderma	0.000196	0.00117	CcSEcCtD
Regadenoson—Dizziness—Mycophenolic acid—systemic scleroderma	0.000195	0.00116	CcSEcCtD
Regadenoson—Rash—Leflunomide—systemic scleroderma	0.000195	0.00116	CcSEcCtD
Regadenoson—Dermatitis—Leflunomide—systemic scleroderma	0.000195	0.00116	CcSEcCtD
Regadenoson—Mental disorder—Prednisone—systemic scleroderma	0.000195	0.00116	CcSEcCtD
Regadenoson—Nausea—Azathioprine—systemic scleroderma	0.000195	0.00116	CcSEcCtD
Regadenoson—Headache—Leflunomide—systemic scleroderma	0.000194	0.00115	CcSEcCtD
Regadenoson—Erythema—Prednisone—systemic scleroderma	0.000194	0.00115	CcSEcCtD
Regadenoson—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000192	0.00114	CcSEcCtD
Regadenoson—Asthenia—Lisinopril—systemic scleroderma	0.000191	0.00113	CcSEcCtD
Regadenoson—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000191	0.00113	CcSEcCtD
Regadenoson—Vomiting—Mycophenolic acid—systemic scleroderma	0.000188	0.00112	CcSEcCtD
Regadenoson—Rash—Mycophenolic acid—systemic scleroderma	0.000186	0.00111	CcSEcCtD
Regadenoson—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000186	0.00111	CcSEcCtD
Regadenoson—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000185	0.0011	CcSEcCtD
Regadenoson—Headache—Mycophenolic acid—systemic scleroderma	0.000185	0.0011	CcSEcCtD
Regadenoson—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000184	0.0011	CcSEcCtD
Regadenoson—Nausea—Leflunomide—systemic scleroderma	0.000184	0.00109	CcSEcCtD
Regadenoson—Vision blurred—Prednisone—systemic scleroderma	0.000183	0.00108	CcSEcCtD
Regadenoson—Diarrhoea—Lisinopril—systemic scleroderma	0.000182	0.00108	CcSEcCtD
Regadenoson—Ill-defined disorder—Prednisone—systemic scleroderma	0.00018	0.00107	CcSEcCtD
Regadenoson—Angioedema—Prednisone—systemic scleroderma	0.000177	0.00105	CcSEcCtD
Regadenoson—Dizziness—Lisinopril—systemic scleroderma	0.000176	0.00105	CcSEcCtD
Regadenoson—Nausea—Mycophenolic acid—systemic scleroderma	0.000176	0.00104	CcSEcCtD
Regadenoson—Malaise—Prednisone—systemic scleroderma	0.000175	0.00104	CcSEcCtD
Regadenoson—Eye disorder—Methotrexate—systemic scleroderma	0.000174	0.00103	CcSEcCtD
Regadenoson—Syncope—Prednisone—systemic scleroderma	0.000174	0.00103	CcSEcCtD
Regadenoson—Tinnitus—Methotrexate—systemic scleroderma	0.000173	0.00103	CcSEcCtD
Regadenoson—Cardiac disorder—Methotrexate—systemic scleroderma	0.000173	0.00103	CcSEcCtD
Regadenoson—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000172	0.00102	CcSEcCtD
Regadenoson—Loss of consciousness—Prednisone—systemic scleroderma	0.00017	0.00101	CcSEcCtD
Regadenoson—Vomiting—Lisinopril—systemic scleroderma	0.000169	0.00101	CcSEcCtD
Regadenoson—Angiopathy—Methotrexate—systemic scleroderma	0.000169	0.001	CcSEcCtD
Regadenoson—Immune system disorder—Methotrexate—systemic scleroderma	0.000168	0.000998	CcSEcCtD
Regadenoson—Rash—Lisinopril—systemic scleroderma	0.000168	0.000997	CcSEcCtD
Regadenoson—Convulsion—Prednisone—systemic scleroderma	0.000168	0.000997	CcSEcCtD
Regadenoson—Dermatitis—Lisinopril—systemic scleroderma	0.000168	0.000996	CcSEcCtD
Regadenoson—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000168	0.000996	CcSEcCtD
Regadenoson—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000994	CcSEcCtD
Regadenoson—Hypertension—Prednisone—systemic scleroderma	0.000167	0.000994	CcSEcCtD
Regadenoson—Headache—Lisinopril—systemic scleroderma	0.000167	0.000991	CcSEcCtD
Regadenoson—Myalgia—Prednisone—systemic scleroderma	0.000165	0.00098	CcSEcCtD
Regadenoson—Arthralgia—Prednisone—systemic scleroderma	0.000165	0.00098	CcSEcCtD
Regadenoson—Anxiety—Prednisone—systemic scleroderma	0.000164	0.000977	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000164	0.000973	CcSEcCtD
Regadenoson—Discomfort—Prednisone—systemic scleroderma	0.000163	0.000968	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—systemic scleroderma	0.000163	0.000968	CcSEcCtD
Regadenoson—Erythema—Methotrexate—systemic scleroderma	0.000162	0.000962	CcSEcCtD
Regadenoson—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00016	0.000948	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—systemic scleroderma	0.000159	0.000942	CcSEcCtD
Regadenoson—Nausea—Lisinopril—systemic scleroderma	0.000158	0.00094	CcSEcCtD
Regadenoson—Anaphylactic shock—Prednisone—systemic scleroderma	0.000158	0.000939	CcSEcCtD
Regadenoson—Shock—Prednisone—systemic scleroderma	0.000156	0.000924	CcSEcCtD
Regadenoson—Nervous system disorder—Prednisone—systemic scleroderma	0.000155	0.000921	CcSEcCtD
Regadenoson—Tachycardia—Prednisone—systemic scleroderma	0.000154	0.000917	CcSEcCtD
Regadenoson—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000917	CcSEcCtD
Regadenoson—Skin disorder—Prednisone—systemic scleroderma	0.000154	0.000913	CcSEcCtD
Regadenoson—Hyperhidrosis—Prednisone—systemic scleroderma	0.000153	0.000908	CcSEcCtD
Regadenoson—Vision blurred—Methotrexate—systemic scleroderma	0.000153	0.000907	CcSEcCtD
Regadenoson—Ill-defined disorder—Methotrexate—systemic scleroderma	0.00015	0.000893	CcSEcCtD
Regadenoson—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000148	0.000881	CcSEcCtD
Regadenoson—Rash—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000874	CcSEcCtD
Regadenoson—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000873	CcSEcCtD
Regadenoson—Headache—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000868	CcSEcCtD
Regadenoson—Malaise—Methotrexate—systemic scleroderma	0.000146	0.000868	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000144	0.000856	CcSEcCtD
Regadenoson—Insomnia—Prednisone—systemic scleroderma	0.000143	0.00085	CcSEcCtD
Regadenoson—Paraesthesia—Prednisone—systemic scleroderma	0.000142	0.000844	CcSEcCtD
Regadenoson—Cough—Methotrexate—systemic scleroderma	0.000141	0.000839	CcSEcCtD
Regadenoson—Convulsion—Methotrexate—systemic scleroderma	0.00014	0.000834	CcSEcCtD
Regadenoson—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000139	0.000823	CcSEcCtD
Regadenoson—Chest pain—Methotrexate—systemic scleroderma	0.000138	0.000819	CcSEcCtD
Regadenoson—Myalgia—Methotrexate—systemic scleroderma	0.000138	0.000819	CcSEcCtD
Regadenoson—Arthralgia—Methotrexate—systemic scleroderma	0.000138	0.000819	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000137	0.000813	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—systemic scleroderma	0.000136	0.000809	CcSEcCtD
Regadenoson—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000132	0.000785	CcSEcCtD
Regadenoson—Feeling abnormal—Prednisone—systemic scleroderma	0.00013	0.000774	CcSEcCtD
Regadenoson—Nervous system disorder—Methotrexate—systemic scleroderma	0.00013	0.00077	CcSEcCtD
Regadenoson—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000129	0.000768	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—systemic scleroderma	0.000128	0.000763	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000128	0.000759	CcSEcCtD
Regadenoson—Urticaria—Prednisone—systemic scleroderma	0.000126	0.000746	CcSEcCtD
Regadenoson—Abdominal pain—Prednisone—systemic scleroderma	0.000125	0.000743	CcSEcCtD
Regadenoson—Hypotension—Methotrexate—systemic scleroderma	0.000123	0.000734	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.00012	0.000715	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—systemic scleroderma	0.000119	0.00071	CcSEcCtD
Regadenoson—Paraesthesia—Methotrexate—systemic scleroderma	0.000119	0.000705	CcSEcCtD
Regadenoson—Dyspnoea—Methotrexate—systemic scleroderma	0.000118	0.0007	CcSEcCtD
Regadenoson—Somnolence—Methotrexate—systemic scleroderma	0.000117	0.000698	CcSEcCtD
Regadenoson—Hypersensitivity—Prednisone—systemic scleroderma	0.000116	0.000692	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000114	0.000678	CcSEcCtD
Regadenoson—Asthenia—Prednisone—systemic scleroderma	0.000113	0.000674	CcSEcCtD
Regadenoson—Pain—Methotrexate—systemic scleroderma	0.000113	0.000671	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—systemic scleroderma	0.000109	0.000647	CcSEcCtD
Regadenoson—Diarrhoea—Prednisone—systemic scleroderma	0.000108	0.000643	CcSEcCtD
Regadenoson—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000108	0.000642	CcSEcCtD
Regadenoson—Urticaria—Methotrexate—systemic scleroderma	0.000105	0.000624	CcSEcCtD
Regadenoson—Dizziness—Prednisone—systemic scleroderma	0.000105	0.000621	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—systemic scleroderma	0.000104	0.000621	CcSEcCtD
Regadenoson—Vomiting—Prednisone—systemic scleroderma	0.0001	0.000597	CcSEcCtD
Regadenoson—Rash—Prednisone—systemic scleroderma	9.97e-05	0.000592	CcSEcCtD
Regadenoson—Dermatitis—Prednisone—systemic scleroderma	9.96e-05	0.000592	CcSEcCtD
Regadenoson—Headache—Prednisone—systemic scleroderma	9.9e-05	0.000589	CcSEcCtD
Regadenoson—Hypersensitivity—Methotrexate—systemic scleroderma	9.73e-05	0.000578	CcSEcCtD
Regadenoson—Asthenia—Methotrexate—systemic scleroderma	9.48e-05	0.000563	CcSEcCtD
Regadenoson—Nausea—Prednisone—systemic scleroderma	9.39e-05	0.000558	CcSEcCtD
Regadenoson—Diarrhoea—Methotrexate—systemic scleroderma	9.04e-05	0.000537	CcSEcCtD
Regadenoson—Dizziness—Methotrexate—systemic scleroderma	8.74e-05	0.000519	CcSEcCtD
Regadenoson—Vomiting—Methotrexate—systemic scleroderma	8.4e-05	0.000499	CcSEcCtD
Regadenoson—Rash—Methotrexate—systemic scleroderma	8.33e-05	0.000495	CcSEcCtD
Regadenoson—Dermatitis—Methotrexate—systemic scleroderma	8.32e-05	0.000495	CcSEcCtD
Regadenoson—Headache—Methotrexate—systemic scleroderma	8.28e-05	0.000492	CcSEcCtD
Regadenoson—Nausea—Methotrexate—systemic scleroderma	7.85e-05	0.000466	CcSEcCtD
